Bone Marrow Microenvironment and the Progression of Multiple Myeloma

References

• Barlogie B., Epstein J., Selvanayagam P., Alexanian R. Plasma cell myeloma: new biological insights and advances in therapy. Blood 1989; 73: 865–79
   PubMed Web of Science ®Google Scholar
• Salmon S. E., Seligmann M. B-cell neoplasia in man. Lancet 1974; 2: 1230–5
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F., Gregoretti M. G., Ghia P., Bergui L. In vitro growth of human multiple myeloma: implications for biology and therapy. Hematol J Oncol. Clin. North Am. 1992; 6: 257–71
   PubMed Web of Science ®Google Scholar
• Mac Lennan I. C. M., Chan E. Y. T. The origin of bone marrow plasma cells. Epidemiology and Biology of Multiple Myeloma, G. I. Obrams, M. Potter. Springer-Verlag, Berlin 1991; 129–35
   Google Scholar
• Benner R., Hijmans W., Haajman J. J. The bone marrow: the major source of serum immunoglobulins, but still a neglected site of antibody formation. Clin. exp. Immunol. 1981; 46: 1–8
   PubMed Web of Science ®Google Scholar
• Liu Y. J., Johnson G. D., Gordon J., MacLennan I. C. M. Germinal centres in T-cell dependent antibody responses. Immunol. Today 1992; 13: 17–21
   PubMedGoogle Scholar
• Di Losa R. M., Maeda K., Masuda A., Szakal A. K., Tew J. G. Germinal center B cells and antibody production in the bone marrow. J. Immunol. 1991; 146: 4071–77
   PubMed Web of Science ®Google Scholar
• Hall J. G., Hopkins J., Orlans E. Studies on lymphoblasts in the sheep III: the destination of lymph-borne immunoblasts according to their tissue origin. Eur. J. Immunol. 1977; 7: 30–9
   PubMed Web of Science ®Google Scholar
• Ruiz-Arguelles G. J., Katzmann J. A., Greipp P. R., Gonchoroff N. J., Garton J. P., Kyle R. A. Multiple myeloma: circulating lymphocytes that express plasma cell antigens. Blood 1984; 64: 352–56
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F., Bergui L., Tesio L., Pizzolo G., Malavasi F., Chilosi M., Campana D., van Camp B., Janossy G. Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J. Clin. Invest. 1985; 76: 1243–51
   PubMed Web of Science ®Google Scholar
• Berenson J., Wong R., Kim K., Brown N., Lichtestein A. Evidence of peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood 1987; 70: 1550–53
   PubMed Web of Science ®Google Scholar
• Bergui L., Schena M., Gaidano G., Riva M., Caligaris-Cappio F. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J. Exp. Med 1989; 170: 613–618
   PubMed Web of Science ®Google Scholar
• Warburton Joshua D. E., Gibson J., Brown R. D. CD10-(CALLA)-positive lymphocytes in myeloma: evidence that they are a malignant precursor population and are of germinal centre origin. Leukemia-Lymphoma 1989; 1: 11–20
   Google Scholar
• Osterborg A., Steinitz M., Lewin N., Bergenbrant S., Holm G., Lefvert A. K., Mellstedt H. Establishment of idiotype bearing B-lymphocyte clones from a patient with monoclonal gammopathy. Blood 1991; 78: 2642–49
   PubMed Web of Science ®Google Scholar
• Cozzolino F., Torcia M., Aldinucci D., Rubartelli A., Miliani A., Shaw A. R., Lansdorp P. M., Di Guglielmo R. Production of Interleuchin-1 by bone marrow myeloma cells. Blood 1989; 74: 380–87
   PubMed Web of Science ®Google Scholar
• Mundy G. R., Raisz Cooper L. G.R. A., Schechter G. P., Salmon S. E. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N. Engl. J. Med. 1974; 291: 1041–46
   PubMed Web of Science ®Google Scholar
• Ross Garrett I., Durie B. G. M., Nedwin G. E., Gillespie A., Bringman T., Sabatini M., Bertolini D. R., Mundy G. R. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N. Engl. J. Med. 1987; 317: 526–32
   PubMed Web of Science ®Google Scholar
• Nakamura M., Merchav S., Carter A., Ernst T. J., Demetri G. D., Furukawa Y., Anderson K., Freedman A. S., Griffin J. D. Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells. J. Immunol. 1989; 143: 3543–47
   PubMed Web of Science ®Google Scholar
• Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1989; 332: 83–86
   Web of Science ®Google Scholar
• Klein B., Zhang X. G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517–26
   PubMed Web of Science ®Google Scholar
• Jernberg H., Pettersson M., Kishimoto T., Nilsson K. Heterogeneity in response to Interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines. Leukemia 1991; 5: 255–65
   PubMed Web of Science ®Google Scholar
• Bertolini D. R., Nedwin G. E., Bringman T. S., Smith D. D., Mundy G. R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factor. Nature 1986; 319: 516–18
   PubMed Web of Science ®Google Scholar
• Dinarello C. Biology of Interleukin 1. FASEB J. 1988; 2: 108–15
   PubMed Web of Science ®Google Scholar
• Kodama H., Nose M., Niida S., Yamasaki A. Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J. Exp. Med. 1991; 173: 1291–94
   PubMed Web of Science ®Google Scholar
• Kurihara N., Bertolini D., Suda T., Akiyama Y., Roodman G. D. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J. Immunol. 1990; 144: 4226–30
   PubMed Web of Science ®Google Scholar
• Kishimoto T. The biology of Interleukin-6. Blood 1989; 74: 1–10
   PubMed Web of Science ®Google Scholar
• Nilsson K., Jernberg H., Pettersson M. IL-6 as a growth factor for human multiple myeloma cells-a short overview. Current Topics of Microbiology and Immunology, F. Melchers, M. Potter. Springer Verlag, Berlin 1990; 166: 3–8
   Google Scholar
• Nordan R. P., Potter M. A macrophage derived factor required by plasmacytomas for survival and proliferation in vitro. Science 1986; 233: 566–69
   PubMed Web of Science ®Google Scholar
• Zhang X. C. G., Klein B., Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989; 74: 11–13
   PubMed Web of Science ®Google Scholar
• Anderson K. C., Jones R. M., Morimoto C., Leavitt P., Barut P. A. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989; 73: 1915–24
   PubMed Web of Science ®Google Scholar
• Zhang X. C. G., Bataille R., Jourdan M., Saeland S., Banchereau J., Mannoni P., Klein B. GM-CSF synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 1990; 76: 2599–605
   PubMed Web of Science ®Google Scholar
• Paul S. R., Bennett F., Calvetti J. A., Kelleher K., Wood C. R., O'Hara R. M., Leary A. C., Sibley B., Clark S. C., Williams D. A., Yang Y. C. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc. Natl. Acad. Sci. USA 1990; 87: 7512–16
   PubMed Web of Science ®Google Scholar
• Bataille R., Jourdan M., Zhang X. G., Klein B. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J. Clin. Invest. 1989; 84: 2008–11
   PubMed Web of Science ®Google Scholar
• Klein B., Wijdenes J., Zhang X. G., Jourdan M., Boiron J. M., Brochier J., Liautard J., Merlin M., Clement C., Morel-Fournier B., Lu Z. Y., Mannoni P., Sany J., Bataille R. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78: 1198
   PubMed Web of Science ®Google Scholar
• Niemeyer C. M., Sieff C. A., Mathey-Prevot B., Wimperis J. Z., Bierer B. E., Clark S. C., Nathan D. G. Expression of human Interleukin-3 (multi-CSF) is restricted to human lymphocytes and T-cell tumor lines. Blood 1989; 73: 945–51
   PubMed Web of Science ®Google Scholar
• Kinashi T., Harada N., Severinson E., Tanabe T., Sideras P., Konishi M., Azume C., Tominaga A., Bergshedt-Lindquist S., Takahashi M., Matsuda F., Yaoita Y., Takatsu K., Honjo T. Cloning of complementary DNA encoding T-cell replacing factor and identity with B-cell growth factor II. Nature 1986; 324: 70–73
   PubMed Web of Science ®Google Scholar
• Dexter T. M., Allen T. D., Lajtha L. G. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J. Cell Physiol. 1977; 91: 335–44
   PubMed Web of Science ®Google Scholar
• Dorshkind K. Regulation of hemopoiesis by bone marrow stromal cells and their products. Ann. Rev. Immunol. 1990; 8: 111–37
   PubMed Web of Science ®Google Scholar
• Kinkade P., Lee G., Pietrangeli C. E., Hayashi S. H., Gimble J. Cells and molecules that regulate B lymphopoiesis in bone marrow. Ann. Rev. Immunol. 1989; 7: 111–43
   PubMed Web of Science ®Google Scholar
• Whitlock C. A., Witte O. N. Long term cultures of B lymphocytes and their precursors from murine bone marrow. Proc. Natl. Acad. Sci. U.S.A. 1982; 79: 3608–12
   PubMed Web of Science ®Google Scholar
• Simmons P. J., Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antobody, STRO-1. Blood 1991; 78: 55–62
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F., Bergui L., Gregoretti M. G., Gaidano G., Gaboli M., Schena M., Zambonin-Zallone A., Marchisio P. C. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991; 77: 2688–93
   PubMed Web of Science ®Google Scholar
• Durie B. G. M., Salmon S. E. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842–54
   PubMed Web of Science ®Google Scholar
• Ruoslahti E. Integrins. J. Clin. Invest. 1991; 87: 1–8
   PubMed Web of Science ®Google Scholar
• Williams D. A., Rios M., Stephens C., Patel V. P. Fibronectin and VLA-4 in haematopoietic stem cell-micro-environment interactions. Nature 1991; 352: 438–41
   PubMed Web of Science ®Google Scholar
• Roberts R., Gallagher J., Spooncer E., Allen T. D., Bloomfield F., Dexter T. M. Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature 1988; 332: 376–78
   PubMed Web of Science ®Google Scholar
• Drach J., Gattringer C., Huber H. Expression of the neural cell adhesion molecule (CD56) by human myeloma cells. Clin. exp. Immunol. 1991; 83: 418–22
   PubMed Web of Science ®Google Scholar
• Lewinsohn D. M., Nagler A., Ginzton N., Greenberg P., Butcher E. C. Haematopoietic progenitor cells expression of the H-CAM (CD44) homing-associated adhesion molecule. Blood 1990; 76: 589–94
   Google Scholar
• Van Camp B., Durie B. G. M., Spier C., De Waele M., Van Riet I., Vela E., Frutiger Y., Richter L., Grogan T. M. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 1990; 76: 377–82
   PubMed Web of Science ®Google Scholar
• Barton B. E., Mayer R. IL-3 induces differentiation of bone marrow precursor cells to osteoclast-like cells. J. Immunol. 1989; 143: 3211–15
   PubMed Web of Science ®Google Scholar
• Stashenko P., Dewhirst F. E., Rooney M. L., Desjardins L. A., Heeley J. D. Interleukin-1/J is a potent inhibitor of bone formation in vitro. Bone Min. Res. 1987; 2: 559–64
   Google Scholar
• Nemunaitis J., Andrews F., Mochizuki D., Lilly M. B., Singer J. W. Human marrow stromal cells: response to interleukin-6 (IL-6) and control of II-6 expression. Blood 1989; 74: 1929–36
   PubMed Web of Science ®Google Scholar